Ani Pharmaceuticals (ANIP) Retained Earnings (2016 - 2025)
Historic Retained Earnings for Ani Pharmaceuticals (ANIP) over the last 17 years, with Q3 2025 value amounting to -$50.6 million.
- Ani Pharmaceuticals' Retained Earnings rose 4353.72% to -$50.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$50.6 million, marking a year-over-year increase of 4353.72%. This contributed to the annual value of -$100.3 million for FY2024, which is 2514.23% down from last year.
- Ani Pharmaceuticals' Retained Earnings amounted to -$50.6 million in Q3 2025, which was up 4353.72% from -$76.9 million recorded in Q2 2025.
- Ani Pharmaceuticals' 5-year Retained Earnings high stood at -$5.0 million for Q1 2021, and its period low was -$100.3 million during Q4 2024.
- Moreover, its 5-year median value for Retained Earnings was -$80.1 million (2023), whereas its average is -$69.2 million.
- As far as peak fluctuations go, Ani Pharmaceuticals' Retained Earnings surged by 5695.1% in 2021, and later plummeted by 125731.32% in 2022.
- Ani Pharmaceuticals' Retained Earnings (Quarter) stood at -$47.8 million in 2021, then crashed by 103.68% to -$97.3 million in 2022, then rose by 17.63% to -$80.1 million in 2023, then decreased by 25.14% to -$100.3 million in 2024, then surged by 49.55% to -$50.6 million in 2025.
- Its Retained Earnings was -$50.6 million in Q3 2025, compared to -$76.9 million in Q2 2025 and -$85.0 million in Q1 2025.